Drug intelligence / Profile preview

VL-OV11

Development stage: Unknown
Lead developer: Vitti Labs
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous (based On Clinical Trial Protocols For Similar Products)[10]

Overview

VL-OV11 is an investigational exosome-based therapy derived from human mesenchymal stem cells, developed by Vitti Labs. It is being studied for the treatment of reproductive and endocrine disorders such as primary ovarian insufficiency (POI) and polycystic ovary syndrome (PCOS), as well as post-acute COVID-19 syndrome. The product leverages the regenerative and immunomodulatory properties of exosomes—small extracellular vesicles secreted by mesenchymal stem cells—to potentially restore ovarian function and modulate immune responses in target diseases. Clinical development has reached Phase 2 for several indications[1][2].

Brand names: EV-Pure
Other names: Exosomes From Human Mesenchymal Stem Cells (Vitti Labs)

Beyond the preview

Go deeper on VL-OV11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VL-OV11.

Explore the full profile